Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bioavailability enhancement refers to a set of formulation and chemical strategies applied to pharmaceuticals to increase the proportion of an administered active pharmaceutical ingredient (API) that reaches systemic circulation and the site of action. Techniques for bioavailability enhancement include improving drug solubility (through nanoparticle formation, solid dispersions, salt formation, or micellization), increasing permeability, reducing particle size (micronization or nanonization), using permeability and metabolism enhancers, and optimizing formulation through excipients or delivery systems[1][2][3][4][5][6][7][8]. This is especially important for drugs with poor water solubility (such as BCS Class II and Class IV compounds), as low bioavailability can limit therapeutic efficacy, require higher doses, and cause greater side effects. While bioavailability enhancement is crucial in drug development, it describes a technological process and not a discrete molecular target, and thus is not appropriately classified as a therapeutic target for pharmacological intervention[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bioavailability enhancement.